AstraZeneca's selumetinib stumbles in Phase III
This article was originally published in Scrip
One of AstraZeneca's key prospects in oncology, selumetinib, has failed in at the Phase III stage in one of its potential indications, uveal melanoma.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
AstraZeneca's novel targeted anticancer selumetinib has missed its endpoints in a Phase III study in lung cancer, the second late-stage failure for the product, which last year disappointed in uveal melanoma.
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.